

Claims

1. A combination comprising as a first active ingredient 6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide or a prodrug or pharmaceutically acceptable salt thereof and as a second active ingredient pyronaridine or a prodrug or pharmaceutically acceptable salt thereof.
2. A combination according to claim 1, which comprises as a third active ingredient artemisinin or a derivative or pharmaceutically acceptable salt thereof.
3. A combination according to claim 2, wherein the artemisinin derivative is selected from a group consisting of: dihydroartemisin and artemether, artesunate.
4. A combination according to claim 3, which wherein the third active ingredient is artesunate or a pharmaceutically acceptable salt thereof.
5. A combination according to claim 4, wherein the pharmaceutically acceptable salt of artesunate is salt selected from a group consisting of: sodium salts and potassium salts.
6. A combination according to any of claims 2 to 5, wherein the combination comprises 6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide, pyronaridine tetraphosphate and sodium artesunate.
7. A combination according to any of claims 1 to 6, wherein the active ingredients are administered simultaneously or sequentially.
8. A combination comprising according to any of claims 1 to 7 for use in the treatment and/or prevention of malaria.
9. A pharmaceutical composition comprising as active ingredients therapeutically active doses of 6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide or a prodrug or pharmaceutically acceptable salt thereof and pyronaridine or a

pharmaceutically acceptable salt thereof, and also at least one pharmaceutically acceptable excipient, for the treatment and/or prevention of malaria.

10. A pharmaceutical composition according to claim 9, comprising as a further active ingredient a therapeutically active dose of artemisinin or a derivative or pharmaceutically acceptable salt thereof.
11. A kit for the treatment of malaria, comprising firstly 6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide or a pharmaceutically active salt thereof, and secondly pyronaridine or a pharmaceutically active salt thereof.
12. A kit according to claim 11, which further comprises artemisinin or a derivative or pharmaceutically acceptable salt thereof.
13. A method for the treatment and/or prevention of malaria in a patient in need thereof, comprising administering to such patient a therapeutically active amount of a combination of 6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide and pyronaridine or a prodrug or pharmaceutically acceptable salt of any of the any of the foregoing including mixtures thereof in all ratios.